NewEdge Wealth LLC Has $46.62 Million Holdings in Amgen Inc. $AMGN

NewEdge Wealth LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,438 shares of the medical research company’s stock after purchasing an additional 7,521 shares during the quarter. NewEdge Wealth LLC’s holdings in Amgen were worth $46,621,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Robeco Institutional Asset Management B.V. boosted its holdings in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after purchasing an additional 3,619 shares during the period. Curtis Advisory Group LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $1,669,000. Global Wealth Management Investment Advisory Inc. boosted its stake in shares of Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after purchasing an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of Amgen by 18.2% during the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after buying an additional 6,115 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AMGN shares. Canaccord Genuity Group initiated coverage on shares of Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday. Guggenheim lowered their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. UBS Group boosted their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Royal Bank Of Canada upped their target price on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $357.12.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 0.8%

Shares of NASDAQ AMGN opened at $331.70 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $179.01 billion, a PE ratio of 23.08, a P/E/G ratio of 3.33 and a beta of 0.44. The company’s fifty day simple moving average is $355.12 and its 200 day simple moving average is $341.81. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the firm posted $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.36 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.